Impact of Functional Class Change on Survival in Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights from REVEAL

PURPOSE: The Registry to EValuate Early And Long-term Pulmonary Arterial Hypertension (PAH) Disease Management (REVEAL), a 55-center observational, US study, provides current demographic, clinical, and treatment patterns in patients with PAH, including the PAH subgroup congenital heart disease-associated PAH (APAH-CHD). This analysis investigates the association between NYHA functional class (FC) and survival in APAH-CHD.